Government and health authorities make recommendations based on scientific evidence that proves the benefit of a particular therapy outweighs the risks. All medications have side effects and low-dose aspirin is no exception. Aspirin is often prescribed for secondary prevention in people who have had a heart attack or stroke because research demonstrates that in this…Details
We’ve reached a number of very important milestones! Thank you to the ASPREE research team, GP co-investigators and most importantly the generosity of our wonderful participants in the study. ASPREE participants in the US and Australia = 16,500 ASPREE participants in Australia = 14,500 ASPREE participants in Victoria = 10,500 ASPREE participants in Tasmania= 2,000…Details
The US Food and Drug Administration’s (FDA) decision not to recommend aspirin for primary prevention due to a lack of scientific evidence, adds further support for the ASPREE study. In a statement issued on their website, the FDA reported that the potential benefits of aspirin had not yet been established against known risks, such as…Details
ASPREE jumped on board Yarra Trams’ Good Friday Appeal, resulting in two tram faces sporting the ASPREE logo.
The Good Friday Appeal is a major Easter fundraiser for Victoria’s Royal Children’s Hospital. The Yarra Trams initiative reportedly raised more than $30,000.
Senior researchers in the ASPREE (ASPirin in Reducing Events in the Elderly) trial were in Shepparton this week to give the first of several study updates planned for Australian participants this year. Executive Officer of ASPREE, Associate Professor Robyn Woods, presented an update on the aspirin study’s progress at a morning tea for participants living in…Details
ASPREE Principal Investigator in Australia, Professor John McNeil discussed what the findings of ASPREE may mean to future health care in this week’s GP publication ‘Medical Observer’. He wrote: “Currently, it is not known if low-grade inflammation is a cause or consequence of the diseases of ageing. If ASPREE shows lower incidence of disease and disability among those with reduced inflammatory…Details
In 2013, the ASPREE (ASPirin in Reducing Events in the Elderly) study reached a number of significant milestones that could not have been reached without the generosity of older Australians, supporting GPs and practice staff and our hard-working team. Congratulations to all. Fun facts about ASPREE in 2013. The trial: • Reached and exceeded the original…Details
Fantastic to meet so many of our participants and guests at ASPREE study updates in Melbourne, Traralgon, Adelaide and Hobart in 2013. We look forward to seeing you again in 2014.
ASPREE’s biannial participant newsletter is in the post! In this edition, John McNeil thanks our participants for pitching in to help solve big health issues facing older people. We give updates on sub-studies in Australia such as ASPREE – AMD (age-related macular degeneration) and ASPREE-NEURO, to determine whether brain MRIs can accurately predict the risk of stroke…Details
The ASPREE study does not have preliminary findings at this point in time – the trial is still in the recruitment phase and will continue to be so until mid 2014. If you have further questions, please ring 1800 728 745 (toll free from a landline).